tirzepatide surpass 2 Efficacy of in phase (GPGB; [14]) and phase 3 (SURPASS-1 SURPASS-CVOT: Tirzepatide Significantly Reduces Major
Pay in 4 interest-free payments of $6.62 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
![tirzepatide surpass 2 Efficacy of in phase (GPGB; [14]) and phase 3 (SURPASS-1 SURPASS-CVOT: Tirzepatide Significantly Reduces Major](https://mumcdnstorage.blob.core.windows.net/dwnews/2026/05/iStock-2211882789.jpg)
![tirzepatide surpass 2 Efficacy of in phase (GPGB; [14]) and phase 3 (SURPASS-1 SURPASS-CVOT: Tirzepatide Significantly Reduces Major](https://www.researchgate.net/publication/374430236/figure/fig1/AS:11431281779073102@1765328936047/Flow-of-Participants-in-the-SURPASS-6-Trial-See-Table-3-for-the-details-of-the-adverse.png)
![tirzepatide surpass 2 Efficacy of in phase (GPGB; [14]) and phase 3 (SURPASS-1 SURPASS-CVOT: Tirzepatide Significantly Reduces Major](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01733-2/MediaObjects/41591_2022_1733_Fig1_HTML.png)












.webp)


/assets/images/provider/photos/2802570.png)




